10-K/A: BioLife Solutions Files Amendment to 2024 Annual Report, Restating Part III and Filing New Certifications

BioLife Solutions has filed an amendment to its 2024 Annual Report to restate Part III, covering directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, director independence, and principal accounting fees, and to file new certifications.

Summary

• BioLife Solutions filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment restates Part III, Items 10 through 14, which include information on directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, director independence, and principal accounting fees and services.
• New certifications from the principal executive officer and principal financial officer are filed as exhibits.
• The original 2024 Annual Report was filed on March 3, 2025.
• As of March 27, 2025, BioLife Solutions had 47.5 million shares of common stock outstanding.
• The aggregate market value of common equity held by non-affiliates as of June 28, 2024, was approximately $784 million.
• The company successfully divested Global Cooling, Custom Biogenics, and SciSafe, generating approximately $74.7 million in cash during the year ended December 31, 2024.
• Revenue increased to $82.3 million, an 8% year-over-year gain compared to $75.9 million in 2023.
• Adjusted EBITDA was $15.6 million, or 19% of revenue.
• The Compensation Committee determined that the Company achieved the Company Objectives at 88% of target levels.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with revenue growth and successful divestitures, but the presence of a new material weakness tempers the overall sentiment.

Positives

• Revenue increased to $82.3 million, an 8% year-over-year gain.
• Adjusted EBITDA was $15.6 million, or 19% of revenue.
• The company successfully divested Global Cooling, Custom Biogenics, and SciSafe, generating approximately $74.7 million in cash.
• All material weaknesses from 2023 were remediated.

Negatives

• The Company incurred one new material weakness in 2024.
• The NetSuite MRP module was not fully implemented on the media product line.

Risks

• The document does not explicitly outline risks, but the presence of a material weakness indicates potential internal control issues.
• Failure to fully implement the NetSuite MRP module on the media product line could impact operational efficiency.

Future Outlook

The company is focused on streamlining its business to return the greatest value to customers and shareholders, strengthening its product portfolio, and optimizing long-term value.

Management Comments

• The Company believes that the compensation of its executive officers should align the executive officers interests with those of the shareholders and focus executive officer behavior to achieve both near-term corporate goals and long-term business and strategies.
• The Compensation Committee determined that the structure of our executive compensation policies continues to be appropriately aligned to the achievement of Company goals and objectives and the best interests of shareholders.

Industry Context

BioLife Solutions operates in the biopreservation and cell and gene therapy space, competing with companies offering bioprocessing products and services. The company's divestitures suggest a strategic shift towards focusing on its core biopreservation media and cell processing products.

Comparison to Industry Standards

• The peer group used for benchmarking executive compensation includes companies like AngioDynamics, Cryoport, MaxCyte, and Cerus Corporation.
• The peer group companies had revenues ranging from 50% to 900% of BioLife Solutions' revenue for the most recent year ended December 31, 2023.
• The Compensation Committee generally targets each NEOs total compensation to be near the 50th percentile of the peer group.

Management Changes

Stakeholder Impact

• Shareholders benefit from the company's focus on streamlining operations and increasing shareholder value.
• Employees are impacted by changes in executive compensation and potential restructuring efforts.
• Customers benefit from the company's focus on improving its product portfolio and services.

Next Steps

• The company will continue to prioritize efficiencies in its proprietary cell processing products and services.
• BioLife will deepen relationships with existing biopreservation media customers.
• The company will emphasize cross-selling of other cell processing products and services.
• BioLife will continue to optimize its long-term value to its customers and shareholders.

Key Dates

Keywords

executive compensation, corporate governance, directors, financial performance, amendment, annual report, biopreservation, BioLife Solutions